{"name":"Sunshine Lake Pharma Co., Ltd.","slug":"sunshine-lake-pharma-co-ltd","ticker":"","exchange":"","domain":"hecpharm.com","description":"","hq":"Guandong","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"immunology","drugs":[{"name":"GLS4","genericName":"GLS4","slug":"gls4","indication":"Other","status":"phase_2"},{"name":"HEC96719","genericName":"HEC96719","slug":"hec96719","indication":"Other","status":"phase_2"},{"name":"entecavir tablets","genericName":"entecavir tablets","slug":"entecavir-tablets","indication":"Other","status":"marketed"},{"name":"Clifutinib","genericName":"Clifutinib","slug":"clifutinib","indication":"Other","status":"phase_3"},{"name":"HEC585","genericName":"HEC585","slug":"hec585","indication":"Other","status":"phase_3"},{"name":"HEC585 dose A","genericName":"HEC585 dose A","slug":"hec585-dose-a","indication":"Other","status":"phase_2"},{"name":"HEC68498","genericName":"HEC68498","slug":"hec68498","indication":"Other","status":"phase_1"},{"name":"HEC83518","genericName":"HEC83518","slug":"hec83518","indication":"Other","status":"phase_1"},{"name":"Larotinib","genericName":"Larotinib","slug":"larotinib","indication":"Other","status":"phase_1"},{"name":"Lerotinib","genericName":"Lerotinib","slug":"lerotinib","indication":"Other","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"FLAG-IDA","genericName":"FLAG-IDA","slug":"flag-ida","indication":"Acute myeloid leukemia (AML), relapsed or refractory","status":"phase_3"},{"name":"Ara-C±IDA","genericName":"Ara-C±IDA","slug":"ara-c-ida","indication":"Acute myeloid leukemia (AML)","status":"phase_3"},{"name":"Irinotecan/Tegafur","genericName":"Irinotecan/Tegafur","slug":"irinotecan-tegafur","indication":"Colorectal cancer (phase 3 development)","status":"phase_3"},{"name":"LoDAC","genericName":"LoDAC","slug":"lodac","indication":"Acute myeloid leukemia (AML) in elderly or unfit patients","status":"phase_3"}]}],"pipeline":[{"name":"FLAG-IDA","genericName":"FLAG-IDA","slug":"flag-ida","phase":"phase_3","mechanism":"FLAG-IDA is a combination chemotherapy regimen that inhibits DNA synthesis and promotes apoptosis in rapidly dividing cells.","indications":["Acute myeloid leukemia (AML), relapsed or refractory","Acute lymphoblastic leukemia (ALL), relapsed or refractory"],"catalyst":""},{"name":"GLS4","genericName":"GLS4","slug":"gls4","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HEC96719","genericName":"HEC96719","slug":"hec96719","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"entecavir tablets","genericName":"entecavir tablets","slug":"entecavir-tablets","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ara-C±IDA","genericName":"Ara-C±IDA","slug":"ara-c-ida","phase":"phase_3","mechanism":"Ara-C±IDA is a combination chemotherapy regimen that inhibits DNA synthesis and induces apoptosis in rapidly dividing cells.","indications":["Acute myeloid leukemia (AML)","Acute lymphoblastic leukemia (ALL)"],"catalyst":""},{"name":"Clifutinib","genericName":"Clifutinib","slug":"clifutinib","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HEC585","genericName":"HEC585","slug":"hec585","phase":"phase_3","mechanism":"HEC585 is an investigational therapeutic agent in phase 3 development by Sunshine Lake Pharma with an undisclosed mechanism of action.","indications":[],"catalyst":""},{"name":"HEC585 dose A","genericName":"HEC585 dose A","slug":"hec585-dose-a","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HEC68498","genericName":"HEC68498","slug":"hec68498","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HEC83518","genericName":"HEC83518","slug":"hec83518","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Irinotecan/Tegafur","genericName":"Irinotecan/Tegafur","slug":"irinotecan-tegafur","phase":"phase_3","mechanism":"Irinotecan inhibits topoisomerase I to prevent DNA unwinding during replication, while tegafur is a prodrug of fluorouracil that inhibits thymidylate synthase to disrupt nucleotide synthesis.","indications":["Colorectal cancer (phase 3 development)","Gastric cancer (potential indication)"],"catalyst":""},{"name":"Larotinib","genericName":"Larotinib","slug":"larotinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lerotinib","genericName":"Lerotinib","slug":"lerotinib","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LoDAC","genericName":"LoDAC","slug":"lodac","phase":"phase_3","mechanism":"LoDAC is a low-dose cytarabine formulation designed to improve tolerability and efficacy in hematologic malignancies.","indications":["Acute myeloid leukemia (AML) in elderly or unfit patients","Myelodysplastic syndrome (MDS)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxQYUFocV92aUVEMWRIeENveHpoNnRadEJ5TlBWVDN4VjNvc184em0zS2tlR2UzQ0FGdEpuX0phNWdoWXlyd0pIdUgyd3hmWEg5WGRwRlR2bW13QWY0OHhVR3QteU1yTGFkNDdPLU1fMnRKWFJISzVYTkhBMWJzZHFNQk5BSlN2Ulk4bE44OGV0ak1lT0tWZXB1eER0WURMUkozOW1nTW9hUVdTeXBzeENraE50eGYySkM3N0RQeVdTMWlDZ0lzRlJ0M3dPSGhqWC1teUtvc19fS21fVGotY0hNX0dsRTJkbVNOalhr?oc=5","date":"2026-04-08","type":"pipeline","source":"TipRanks","summary":"Sunshine Lake Pharma Wins NMPA Acceptance for Innovative Vonoprazan Injection for Peptic Ulcer Bleeding - TipRanks","headline":"Sunshine Lake Pharma Wins NMPA Acceptance for Innovative Vonoprazan Injection for Peptic Ulcer Bleeding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNVXpCV25oMmg5aTBBVVZ2cGd1OG9aLUR0aTJJQ2ZHeXQ2TWdHU0gweVlLZ2dXbmVhLXlCaG55X1d2M18yT1J2bk5QbEtXY0JoYWZtbmVrWV96MHVBcW4yOWNaMDhVbWtDTGh1Vkc1UG05em1PaGhVYVRpcFZmbUhCaXBYVU5NcGNXbGljY29fSVUwTzhabmUzSDg3OXk1RS1zc0drUFBPSXJ5WFVyVmZ4RXRVSG92Tk11cFJoVG5sdmFxZTNJdk4wNmQ1VTBGSnNUZ09fbXN4NGpRZEgxYUJzZURPclZ3WnFjNlhaclEwWXBCSGZqdC1QMzNaMXU?oc=5","date":"2026-04-07","type":"trial","source":"Barchart.com","summary":"Influenza Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com","headline":"Influenza Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Develop Drugs for Market Entry | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE42VzFfaUtBVHBhZllheTdGRkFqZ1E5VjZHc3NiZVRkaG9IYm1xU2k1RkVXcmVhR0kxRl8yR3I5MUpKODNyQUFLQ3hTMkZ6UkRsa0hXNG9iRmY?oc=5","date":"2026-04-07","type":"pipeline","source":"minichart.com.sg","summary":"Sunshine Lake Pharma Co., Ltd. Class H (6887.HK) - minichart.com.sg","headline":"Sunshine Lake Pharma Co., Ltd. Class H (6887.HK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQVENMTGV0Yktxb1hKMG9tQlFTUEMwUVhueXY2TWhOOTJDZEJ3bzBXQ1Z3Y1FFWXVyakVQaG5PYnFOdmEzYmVYdmRNYWFPMFFMMnhSSnVGd0J4cGNwRFltMkNuRXlVUEZvX0ctOHlUOEZIa240UEdQdU9HQmhUQllxMUdnbHB5Y00tVjA5TUJZLXpSdVl1bXJ0N2haZmFKSjNhYnJTdWhpOFk4c0hSbmExM3Qxbw?oc=5","date":"2026-03-31","type":"earnings","source":"marketscreener.com","summary":"Sunshine Lake Pharma posts FY revenue of RMB4,815.07 million - marketscreener.com","headline":"Sunshine Lake Pharma posts FY revenue of RMB4,815.07 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOUTUyc18wSWItS1JENVhMMms2TW5jVmswenFKTXRHdE1OREk0OFlGa0ZFcm9nNWZ3eUJVZi15YnNEaGgxbXJZTF9aSk0tMUlIU1dxSnllSW1Sa0dsUnpMclFrbXdfMzNXQlZKRE9xeS00Q1ZJSFMxeTRLaDE5d0U2WkNsT2cyY01qY1pHZk8zc1BCeWxXMTFpNTZsMXZFaUs1ajNjSWV3TTV1ZXZiQTZPZHNjU2wxRG0xUm5qLXpxdHNxejQ?oc=5","date":"2026-03-31","type":"earnings","source":"TipRanks","summary":"Sunshine Lake Pharma Swings to Profit on Double-Digit 2025 Revenue Growth - TipRanks","headline":"Sunshine Lake Pharma Swings to Profit on Double-Digit 2025 Revenue Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQemkyUWtFVmN1bDQ5YU1CbVlmTVdSVnhxUGlFaTlVMkNZVkFRTHo3OU5PNXBwWWJPMVRRSjh0dDFFd1FKMUpULXozN1IzMnBNRnlEY3dSalBCWlJIdWpidVVVMFVtb1BJc19OSFg2Z3M0RDVjVFhrM1M3eUdkZVNYVmFhR3ZKM2NjYnVFZTlVQ0dtZmZybmtNMkxmN0FzXzljZXBaWEFKUzktX1dhcEJQbHRsWHQ0a3hrY19ranBlZTNrZF9Z?oc=5","date":"2025-08-19","type":"deal","source":"Citeline News & Insights","summary":"China-Originated Assets Lead Global GLP-1 Deals - Citeline News & Insights","headline":"China-Originated Assets Lead Global GLP-1 Deals - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-07","type":"pipeline","source":"South China Morning Post","summary":"Sunshine Lake Pharma falls in Hong Kong stock market debut - South China Morning Post","headline":"Sunshine Lake Pharma falls in Hong Kong stock market debut","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE0zdF84MXc5TEVncUg1bi01dUFqaW52SHJMOGZEeXBSNDVrMEZkVXdMWFVWQlpUU0V6YzktNVVDcFZBT0FPSGlfRVU0dzIwYmp6THZVMnVCdDR0bHZDYmx4ODNLSnVpa0FSNngwbFJVZDN3aTVJ?oc=5","date":"2025-08-06","type":"pipeline","source":"TradingView","summary":"Sunshine Lake Pharma Co., Ltd. Class H Financial Statements – HKEX:6887 - TradingView","headline":"Sunshine Lake Pharma Co., Ltd. Class H Financial Statements – HKEX:6887","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTFBkcHZyZm4xWmJleUxfUTRxOWloNjdDQi1nNVNsN0NIUTUxd2dXT0lZMEhxN0tpWkgzYkF5d2oyejZGTzZnWndQSGttZ25ISW9CcHYyMGNjb3d2Zw?oc=5","date":"2025-08-06","type":"pipeline","source":"TradingView","summary":"6887 Stock Price and Chart — HKEX:6887 - TradingView","headline":"6887 Stock Price and Chart — HKEX:6887","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE55bDhGQmo4TzczZ0NyemtIMk90a2NvTzRvNmdmRFN3ZFk2cWlHUEd0a1FDVzNYMkRmVU15ZDJvaHVOZWstTU9UZml1SC1nd1Y2VEpZOFVqQ0JaYzE4TWlYazJRSEhGZWNjblBIRElsNVlPNFBIVllZSFExaDdaQQ?oc=5","date":"2025-08-05","type":"pipeline","source":"Yahoo Finance","summary":"Sunshine Lake Pharma Co., Ltd. (06887.HK) Completes Listing, Market Capitalisation Expected to Rapidly Surpass RMB 50 Billion - Yahoo Finance","headline":"Sunshine Lake Pharma Co., Ltd. (06887.HK) Completes Listing, Market Capitalisation Expected to Rapidly Surpass RMB 50 Bi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE1xdzdDSWlUTXFmdGlyclFnTldHenptempSUlNnUkUwX2pqX0NISjlncFh0amJxWHlXZ1hXZlVWTFFQVmhaTlZPVy1vZ0lwUlpwd2lhYnVR?oc=5","date":"2025-08-05","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Sunshine Lake Pharma Co., Ltd. (6887.HK) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Sunshine Lake Pharma Co., Ltd. (6887.HK) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQRmdITkIzU1l0cTZ1VjZreGFMS19VLUxPOFdLLW9xeWdxMkIzaEg3VnJJSEk3SzBsSFNibUxSWTlpM1ZRcWthNllUT1d0OVBnd1lUUG85RkdUOWlrQWJIMHNyVElvVi1MUlNmczJNNUpZSV9QSlNQS3BCREVhYS1LS01nRUhESk9Ic0lLOGdkOHN2QjRHZlRESVdnbTdjbHdlTURz?oc=5","date":"2025-07-24","type":"pipeline","source":"BioWorld News","summary":"34 mainland China biotechs file for Hong Kong IPO in H1 2025 - BioWorld News","headline":"34 mainland China biotechs file for Hong Kong IPO in H1 2025","sentiment":"neutral"}],"patents":[],"drugCount":14,"phaseCounts":{"phase_3":7,"phase_2":3,"marketed":1,"phase_1":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}